As circulating levels of NF-L and MAP2 were found to correlate with clinical and tissue-related outcomes in stroke patients (e.g., Uphaus et al., 2019; Mages et al., 2021), MFAP5 could also be applied as a serum marker that may help to tailor individual treatments. The gene discussed is MAP2; the disease is stroke disorder.